Recently, researchers at the Texas Children’s Hospital and Baylor College of Medicine have developed a new Covid-19 vaccine called Cobrevax against the Delta variant that is 80% effective.


The latest output data from the human trials have shown the vaccine is safe and effective to use.

India has already authorized the use of Cobrevax and the production capacity ramps up to over 100 million doses per month.


One of the reasons Cobrevax is so special is that it is patent-free and that its lab data is open-source.

This means any vaccine manufacturers across the world are allowed to produce the vaccine on their own. 



In late 2020, the US team working on the vaccine partnered with India’s Biological E to begin clinical trials and set up manufacturing capability. 

A total of several thousand participants took part in those clinical trials across 2021 and ultimately found Corbevax to be safe and effective at generating robust immune responses to SARS-CoV-2.


The data from the clinical trial was then compared to an already approved Indian version of Astrazeneca’s well-known COVID-19 vaccine called Covishield. 

The results showed that Corbevax only has fewer adverse effects than Covishield.

Covid19 vaccine
The initial Corbevax vaccine research was led by Maria Elena Bottazzi and Peter Hotez from the Texas Children’s Hospital Center for Vaccine DevelopmentTexas Children’s Hospital




Just like all other vaccines, Cobrevax focuses on the spike protein of Coronavirus. 

But instead of directing our cells to produce these spike proteins internally using mRNA, this vaccine delivers spike proteins that are grown in the laboratory.



“Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world,” said Dr. Maria Elena Bottazzi, a lead researcher on the project.


“The transition of our vaccine candidate into human trials is an important milestone and exemplifies a successful transfer of technology with Biological E that could lead to a safe, effective, and affordable vaccine,” she said.



It is hypothesized that Cobrevax might be effective against the Omicron variant. But it is yet to be confirmed. 


“This vaccine represents an urgent biotechnology innovation for ensuring health equity and combating the COVID-19 pandemic,” said Dr. Peter Hotez, co-director of Texas Children’s Hospital Center for Vaccine Development.

Peter Hotez has described the patent-free vaccine as a “gift to the world.”



Now, the technology has been transferred to vaccine manufacturers in India, Bangladesh, Botswana, and Indonesia.


Read more Good News.